Table 1 Influence of dapagliflozin on clinical parameters in newly diagnosed T2D patients

Age,y

47.5 ± 12.6

Gender, F/M, n

28/29

BMI, kg/m²

28.17 ± 2.70

26.57 ± 3.33

0.000

TG, mmol/L

1.75 (1.32–2.29)

1.48 (1.12–2.22)

0.083

TC, mmol/L

5.21 ± 1.04

5.10 ± 0.94

0.296

HDL-C, mmol/L

1.15 ± 0.27

1.18 ± 0.30

0.122

LDL-C, mmol/L

3.56 ± 1.02

3.43 ± 0.95

0.222

NEFA, mmol/L

0.71 ± 0.21

0.75 ± 0.22

0.199

FBG, mmol/L

8.78 ± 1.78

6.33 ± 0.91

0.000

FINS, mIU/L

11.60 (8.40–17.00)

9.60(6.65–14.92)

0.026

HOMA-IR

4.34 (2.97–6.43)

2.89 (1.75–4.14)

0.000

HbA1c, %

8.38 ± 1.05

6.59 ± 0.55

0.000

CREA, mmol/L

60.43 ± 11.66

61.77 ± 11.51

0.098

eGFR, mL/min/1.73m²

111.30 ± 10.51

109.91 ± 11.01

0.028